EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study

Qingyao Shang, Kexin Feng, Ya Wei, Kaipeng Wang, Chenxuan Yang, Shuangtao Zhao, Jiaxiang Liu, Xiangzhi Meng, Yalun Li, Chuang Du, Jing Wang, Guangdong Qiao und 3 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad189 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Qingyao Shang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Breast Neoplasms, Male, Breast Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Breast Cancer Single Disease Diagnosis and Treatment Capacity Enhancement Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sentinel lymph node biopsy (SLNB) is currently used as a routine treatment for patients with breast cancer. However, it may not be applicable for patients with male breast cancer (MBC), because they have notably different clinicopathological features from those occurring in females. There is a lack of evidence of SLNB application and safe exemption from axillary lymph node dissection (ALND) in patients with MBC. This study aimed to evaluate the application of SLNB to provide information for the standardized treatment of patients with MBC. The MBC patient records from 4 institutions ranging from January 2001 to November 2020 were retrospectively reviewed. There were 220 patients with MBC with a median age of 60 (range 24-88) years and an average tumor size of 2.3 cm (range 0.5 cm-6.5 cm). Sixty-six percent of patients underwent SLNB, and 39% of them showed positive results. A total of 157 patients underwent ALND, while only half of them had positive nodes, causing unnecessary complications. For patients in the clinical early stage, we found that the SLNB showed a noninferiority to the ALND treatment in DFS (P = .18) and OS (P = .055). In conclusion, there are certain obstacles to the broad application of SLNB due to the lower proportion of patients with clinically negative lymph nodes. However, it is undeniable that SLNB can safely and effectively exempt patients with MBC at early stage with clinically negative nodes from ALND to reduce subsequent complications. It is still an ideal criterion for the axillary staging of patients with MBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast Neoplasms, MaleBreast NeoplasmsSentinel Lymph NodeFemaleHumansMaleYoung AdultAdultMiddle AgedAgedAged, 80 and overSentinel Lymph Node BiopsyRetrospective StudiesLymphatic MetastasisLymph Node ExcisionAxillaLymph Nodes

Stichwörter der Autor:innen

axillary lymph node dissectionearly breast cancermale breast cancersentinel lymph node biopsy

Autor:innen und Institutionen

  • Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republ…
  • Department of Breast Surgery, Anyang Cancer Hospital, Henan, People's Republic of China.
  • Department of Medical Record, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of Chin…
  • Department of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Department of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, People's Republic of China.
  • Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • Breast Cancer Single Disease Diagnosis and Treatment Capacity Enhancement Project

Zitieren

APA

Shang, Q., Feng, K., Wei, Y., Wang, K., Yang, C., Zhao, S., Liu, J., Meng, X., Li, Y., Du, C., Wang, J., Qiao, G., Li, J., Wang, X., & Wang, X. (2023). Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study. The Oncologist. https://doi.org/10.1093/oncolo/oyad189

Vancouver

Shang Q, Feng K, Wei Y, Wang K, Yang C, Zhao S, et al. Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study. The Oncologist. 2023. doi:10.1093/oncolo/oyad189

BibTeX
@article{Shang2023,
  author = {Shang, Qingyao and Feng, Kexin and Wei, Ya and Wang, Kaipeng and Yang, Chenxuan and Zhao, Shuangtao and Liu, Jiaxiang and Meng, Xiangzhi and Li, Yalun and Du, Chuang and Wang, Jing and Qiao, Guangdong and Li, Jingruo and Wang, Xin and Wang, Xiang},
  title = {Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad189}
}
Kostenlos starten →